84 results
6-K
EX-99.2
REPCF
Replicel Life Sciences Inc.
30 Nov 23
Condensed Consolidated Interim Financial Statements
1:05pm
. This agreement gives YOFOTO an exclusive 15-year geographic license to develop and market the Company's RCT-01 tendon regeneration technology … party. This agreement gave Shiseido an exclusive geographic license to use the Company's RCH-01 hair regeneration technology in Japan, China, South
6-K
EX-99.2
REPCF
Replicel Life Sciences Inc.
24 Oct 23
Condensed Consolidated Interim Financial Statements
11:10am
gives YOFOTO an exclusive 15-year geographic license to develop and market the Company's RCT-01 tendon regeneration technology in Greater China (China … . This agreement gave Shiseido an exclusive geographic license to use the Company's RCH-01 hair regeneration technology in Japan, China, South Korea, Taiwan
6-K
EX-99.2
REPCF
Replicel Life Sciences Inc.
30 May 23
Condensed Consolidated Interim Financial Statements
5:40pm
to develop and market the Company's RCT-01 tendon regeneration technology in Greater China (China, Hong Kong, Macau, and Taiwan).
Intellectual Property … developed by either party. This agreement gave Shiseido an exclusive geographic license to use the Company's RCH-01 hair regeneration technology in Japan
6-K
EX-99.2
REPCF
Replicel Life Sciences Inc.
29 Nov 22
Condensed Consolidated Interim Financial Statements
6:44pm
geographic license to develop and market the Company’s RCT-01 tendon regeneration technology in Greater China (China, Hong Kong, Macau, and Taiwan … RCH-01 hair regeneration technology in Japan, China, South Korea, Taiwan and the ASEAN countries representing a population of approximately 2.1
20-F/A
s9h1gz
12 Sep 22
Annual report (foreign) (amended)
6:17pm
6-K
EX-99.2
p1fthzfeusfl 66x
6 Sep 22
Condensed Consolidated Interim Financial Statements
12:42pm
6-K
EX-99.2
fpkm9ah4
4 Aug 22
Current report (foreign)
11:41am
6-K
EX-99.3
dhe930hpasnyv
4 Aug 22
Current report (foreign)
11:41am
6-K
EX-99.1
oi42vgiraiil
28 Jul 22
Current report (foreign)
2:52pm
6-K
EX-99.4
0q8cx5lgmqtpp7
7 Jul 22
RepliCel Provides Update on Private Placement
3:36pm
6-K
EX-99.1
ab3ot9crx 4kr
29 Mar 22
RepliCel Announces Material Patent Milestones
12:51pm
6-K
EX-99.2
dhccw uwjgd7s
30 Nov 21
Condensed Consolidated Interim Financial Statements
1:50pm
6-K
EX-99.1
8fzos3u1q zpqsjhwy7
16 Nov 21
RepliCel’s Clinical Advisory Team Delivers Skin Rejuvenation Clinical Study Synopsis to its Japanese Regulatory and Clinical Study Management Team
4:03pm
6-K
EX-99.1
uv3qhs 280vz
14 Oct 21
51-102F3 Material Change Report
4:00pm
6-K
EX-99.1
2eoxm44u89mx6
13 Oct 21
RepliCel Life Sciences Appoints One of Japan’s Foremost Regenerative Medicine Industry Business Leaders as Strategic Advisor
12:00am
6-K
EX-99.2
vfo7yp
31 Aug 21
Condensed Consolidated Interim Financial Statements
1:45pm
6-K
EX-99.1
awj74rznzmk2i66t
18 Aug 21
RepliCel Applies for Manufacturing Approval for its Collagen and Tissue Regeneration Cell Therapies
12:38pm
6-K
EX-99.1
998r3ivy2cag52s
18 Aug 21
Current report (foreign)
12:20pm